Aflibercept (2.0 mg) clinical trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This study, called LUCIA, is looking at a new treatment called EYP-1901 for wet age-related macular degeneration (wAMD). Researchers want to see if EYP-1901 is as effective as a standard treatment, aflibercept, over two years for improving or maintaining eyesight.